Analysts Set Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $29.25

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have been given an average recommendation of “Buy” by the seven ratings firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $29.25.

A number of analysts have recently issued reports on EYPT shares. Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th. Royal Bank Of Canada lifted their price target on Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. TD Cowen upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Thursday, January 22nd.

Eyepoint Pharmaceuticals Trading Up 4.3%

EYPT stock opened at $15.33 on Monday. The company’s 50 day moving average is $15.72 and its 200 day moving average is $13.93. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -5.13 and a beta of 1.76. Eyepoint Pharmaceuticals has a 1-year low of $3.91 and a 1-year high of $19.11.

Insider Buying and Selling

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 42,544 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $17.10, for a total transaction of $727,502.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.46% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC lifted its stake in shares of Eyepoint Pharmaceuticals by 1,636.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,900 shares of the company’s stock valued at $27,000 after acquiring an additional 2,733 shares during the last quarter. State of Alaska Department of Revenue purchased a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at approximately $50,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Eyepoint Pharmaceuticals by 51.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after purchasing an additional 1,358 shares in the last quarter. California State Teachers Retirement System grew its stake in Eyepoint Pharmaceuticals by 20.6% in the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock worth $85,000 after purchasing an additional 794 shares during the period. Finally, Russell Investments Group Ltd. purchased a new stake in Eyepoint Pharmaceuticals in the third quarter worth $76,000. Hedge funds and other institutional investors own 99.41% of the company’s stock.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.